Medindia
Medindia LOGIN REGISTER
Advertisement

ForteBio Strengthens Portfolio with New Biosensors for Research and Development

Monday, August 13, 2007 General News
Advertisement
MENLO PARK, Calif., Aug. 13 ForteBio, Inc., a leadingdeveloper of label-free, real-time systems for biomolecular interactionanalysis, today announced two new product extensions to its Octet System. TheAnti-Murine IgG Biosensor- Quantitation grade, and the Streptavidin HighBinding FA Biosensor- Screening grade, extend the Octet System's concentrationdetermination and kinetic analysis capabilities, respectively, broadening theproduct offering into additional research-focused applications.
Advertisement

"We are continually expanding our menu of surface chemistries to serve thegrowing demand for label-free detection in new areas of therapeutic researchand development," said Winnie Wan, President and Chief Executive Officer."Since the launch of the Octet System less than two years ago, we haveresponded quickly to the needs of the research market by developing sevencompatible biosensors that expand the system's applications in therapeuticdevelopment and bioprocessing."
Advertisement

The Anti-Murine IgG Biosensor- Quantitation grade, provides accurateconcentration determination of mouse and rat sera or supernatants. With theOctet System, fast and accurate results for 96 samples can be achieved in 30minutes. The Streptavidin High Binding FA Biosensor- Screening grade, providestriple the binding capacity for increased signal-to-noise ratios. Thesebiosensors enable better kinetic screening and analysis of smaller proteinsand fragment antibodies (Fabs). With increased ratios, custom quantitationassays for most proteins can also be developed.

The Octet System is a label-free, fluidics-free, real-time system forbiomolecular interaction analysis of protein kinetics and Quantitation. It iscurrently used by pharmaceutical and biotechnology companies in applicationsranging from target identification and validation to bioprocess development.

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providinganalytical systems to accelerate the development of therapeutics. Thesesystems enable real-time analysis of biomolecular interactions providinginformation on affinity, kinetics and concentration. Most importantly,ForteBio's analytical capabilities enable better and faster characterizationof drug candidates, thus providing greater value in drug developmentapplications where existing methods have limitations in throughput,performance and cost. The company is headquartered in Menlo Park, Californiawith a wholly owned subsidiary in Shanghai, China. For more information,please visit http://www.fortebio.com.Contact: Winnie Wan, Ph.D. President and Chief Executive Officer 650-322-1360 [email protected]

SOURCE ForteBio, Inc.,
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close